
Paul Eggleton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1554122/publications.pdf Version: 2024-02-01



PAUL FCCLETON

#	Article	IF	CITATIONS
1	Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells. Cancer Immunology, Immunotherapy, 2022, 71, 1655-1669.	4.2	10
2	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers, 2022, 14, 299.	3.7	11
3	CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism. Theranostics, 2022, 12, 1486-1499.	10.0	8
4	DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. Journal of Experimental and Clinical Cancer Research, 2022, 41, 97.	8.6	12
5	Galectin-9 Triggers Neutrophil-Mediated Anticancer Immunity. Biomedicines, 2022, 10, 66.	3.2	11
6	Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer. Cancers, 2022, 14, 1924.	3.7	5
7	CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma. Biomedicines, 2022, 10, 1175.	3.2	16
8	Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine. International Journal of Molecular Sciences, 2021, 22, 2337.	4.1	16
9	The Role of Macrophages in Cancer Development and Therapy. Cancers, 2021, 13, 1946.	3.7	143
10	High Loading Efficiency and Controlled Release of Bioactive Immunotherapeutic Proteins Using Vaterite Nanoparticles. Particle and Particle Systems Characterization, 2021, 38, 2100012.	2.3	7
11	Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by lowâ€dose metformin. Cancer Communications, 2021, 41, 637-641.	9.2	6
12	CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties. Scientific Reports, 2021, 11, 20499.	3.3	11
13	The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer. International Journal of Molecular Sciences, 2020, 21, 7820.	4.1	21
14	The Fabp5/calnexin complex is a prerequisite for sensitization of mice to experimental autoimmune encephalomyelitis. FASEB Journal, 2020, 34, 16662-16675.	0.5	7
15	Engagement of people with multiple sclerosis to enhance research into the physiological effect of hyperbaric oxygen therapy. Multiple Sclerosis and Related Disorders, 2020, 43, 102084.	2.0	6
16	Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial. Clinical Cancer Research, 2020, 26, 4921-4932.	7.0	86
17	DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses. Blood, 2020, 136, 19-20.	1.4	4
18	Galectin-9 Is a Possible Promoter of Immunopathology in Rheumatoid Arthritis by Activation of Peptidyl Arginine Deiminase 4 (PAD-4) in Granulocytes. International Journal of Molecular Sciences, 2019, 20, 4046.	4.1	28

#	Article	IF	CITATIONS
19	CD47 Expression Defines Efficacy of Rituximab with CHOP in Non–Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Cancer Immunology Research, 2019, 7, 1663-1671.	3.4	28
20	The Biophysical Interaction of the Danger-Associated Molecular Pattern (DAMP) Calreticulin with the Pattern-Associated Molecular Pattern (PAMP) Lipopolysaccharide. International Journal of Molecular Sciences, 2019, 20, 408.	4.1	22
21	Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis. Nature Communications, 2019, 10, 533.	12.8	26
22	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. Journal of Investigative Dermatology, 2019, 139, 2343-2351.e3.	0.7	20
23	Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?. Molecular and Cellular Oncology, 2019, 6, 1600349.	0.7	4
24	Development of Bispecific Antibody Derivatives for Cancer Immunotherapy. Methods in Molecular Biology, 2019, 1884, 335-347.	0.9	5
25	The multifaceted role of autophagy in cancer and the microenvironment. Medicinal Research Reviews, 2019, 39, 517-560.	10.5	146
26	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncolmmunology, 2018, 7, e1466016.	4.6	42
27	CD20-selective inhibition of CD47-SIRPα "don't eat me―signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. Oncolmmunology, 2018, 7, e1386361.	4.6	58
28	Calnexin is necessary for T cell transmigration into the central nervous system. JCI Insight, 2018, 3, .	5.0	14
29	CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 2852-2852.	1.4	Ο
30	Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with coâ€existent bronchiectasis. International Journal of Rheumatic Diseases, 2017, 20, 2003-2011.	1.9	33
31	Manipulation of Oxygen and Endoplasmic Reticulum Stress Factors as Possible Interventions for Treatment of Multiple Sclerosis: Evidence for and Against. Advances in Experimental Medicine and Biology, 2017, 958, 11-27.	1.6	6
32	Rab32 connects ER stress to mitochondrial defects in multiple sclerosis. Journal of Neuroinflammation, 2017, 14, 19.	7.2	53
33	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Scientific Reports, 2017, 7, 13301.	3.3	6
34	Could Autophagy Induced by Misfolded Mutant α ₁ â€Antitrypsin Z in Synovitis Explain the Association of α ₁ â€Antitrypsin Z With Increased Anti–Citrullinated Protein Antibody Production in Rheumatoid Arthritis? Comment on the Article by McCarthy etÂal. Arthritis and Rheumatology, 2017, 69, 2403-2404.	5.6	0
35	Carbamylation/citrullination of IgG Fc in bronchiectasis, established RA with bronchiectasis and RA smokers: a potential risk factor for disease. ERJ Open Research, 2017, 3, 00018-2017.	2.6	16
36	Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5. Journal of Investigative Dermatology, 2016, 136, 541-544.	0.7	18

#	Article	IF	CITATIONS
37	Are Rheumatoid Factor, Anti–Citrullinated Protein Antibodies, and Anti–Carbamylated Protein Antibodies Linked by Posttranslational Modification of IgG? Comment on the Article by Koppejan et al. Arthritis and Rheumatology, 2016, 68, 2825-2826.	5.6	5
38	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. OncoImmunology, 2016, 5, e1202390.	4.6	35
39	Calreticulin, a therapeutic target?. Expert Opinion on Therapeutic Targets, 2016, 20, 1137-1147.	3.4	56
40	CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget, 2016, 7, 75130-75144.	1.8	64
41	Editorial: Endoplasmic Reticulum and Its Role in Tumor Immunity. Frontiers in Oncology, 2015, 5, 252.	2.8	1
42	Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity. Frontiers in Oncology, 2015, 5, 7.	2.8	117
43	Bronchiectasis Is a Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2335-2342.	5.6	68
44	The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux. Autophagy, 2015, 11, 1373-1388.	9.1	49
45	The Ever-Expanding Immunomodulatory Role of Calreticulin in Cancer Immunity. Frontiers in Oncology, 2015, 5, 35.	2.8	36
46	Unfolding the complexities of ER chaperones in health and disease: report on the 11th international calreticulin workshop. Cell Stress and Chaperones, 2015, 20, 875-883.	2.9	15
47	CD20 ⁺ T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer. Oncolmmunology, 2015, 4, e999536.	4.6	17
48	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs, 2015, 7, 321-330.	5.2	22
49	Autoantibodies against C1q as a Diagnostic Measure of Lupus Nephritis: Systematic Review and Meta-analysis. Journal of Clinical & Cellular Immunology, 2014, 05, 210.	1.5	18
50	77.â€∱Diverse Pulmonary Insults Lead to Common Anti-Citrullinated Peptide Fine Specificity Profiles and May Promote Autoimmunity in RA. Rheumatology, 2014, 53, i84-i84.	1.9	0
51	Direct and Indirect Rituximabâ€Induced T Cell Depletion: Comment on the Article by Mélet et al. Arthritis and Rheumatology, 2014, 66, 1053-1053.	5.6	10
52	A <scp>CD</scp> 47â€blocking <scp>TRAIL</scp> fusion protein with dual proâ€phagocytic and proâ€apoptotic anticancer activity. British Journal of Haematology, 2014, 164, 304-307.	2.5	15
53	RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients. European Respiratory Journal, 2014, 44, 1082-1085.	6.7	43
54	The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?. Rheumatology, 2014, 53, 1940-1950.	1.9	87

#	Article	IF	CITATIONS
55	CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Multiple Sclerosis and Related Disorders, 2014, 3, 650-658.	2.0	49
56	A6.3â€Patients with bronchiectasis, with or without rheumatoid arthritis, have an elevated anti-citrullinated peptide antibodies (ACPA) response Annals of the Rheumatic Diseases, 2014, 73, A71.2-A72.	0.9	2
57	Detection and Characterization of Autoantibodies Against Modified Self-Proteins in SLE Sera After Exposure to Reactive Oxygen and Nitrogen Species. Methods in Molecular Biology, 2014, 1134, 163-171.	0.9	14
58	Meta-analysis as a Diagnostic Tool for Predicting Disease Onset and/or Activity in Systemic Lupus Erythematosus. Methods in Molecular Biology, 2014, 1134, 249-259.	0.9	1
59	Bifunctional Antibody Fragment-Based Fusion Proteins for the Targeted Elimination of Pathogenic T-Cell Subsets. Methods in Molecular Biology, 2014, 1134, 79-93.	0.9	1
60	Therapeutic potential of Galectinâ€9 in human disease. Medicinal Research Reviews, 2013, 33, E102-26.	10.5	120
61	Oxidative Stress in Rheumatoid Arthritis. , 2013, , 145-167.		8
62	Detection and isolation of human serum autoantibodies that recognize oxidatively modified autoantigens. Free Radical Biology and Medicine, 2013, 57, 79-91.	2.9	27
63	Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. ISRN Oncology, 2013, 2013, 1-25.	2.1	65
64	Hyperbaric oxygen treatment reduces neutrophilâ€endothelial adhesion in chronic wound conditions through <scp>S</scp> â€nitrosation. Wound Repair and Regeneration, 2013, 21, 860-868.	3.0	28
65	The natural organosulfur compound dipropyltetrasulfide prevents HOCl-induced systemic sclerosis in the mouse. Arthritis Research and Therapy, 2013, 15, R167.	3.5	16
66	Galectin-9 Activates and Expands Human T-Helper 1 Cells. PLoS ONE, 2013, 8, e65616.	2.5	43
67	Different oxygen treatment pressures alter inflammatory gene expression in human endothelial cells. Undersea and Hyperbaric Medicine, 2013, 40, 115-23.	0.3	16
68	The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells. Journal of Investigative Dermatology, 2012, 132, 2302-2305.	0.7	35
69	Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes. International Journal of Biochemistry and Cell Biology, 2012, 44, 1223-1231.	2.8	30
70	Changes in inflammatory gene expression induced by hyperbaric oxygen treatment in human endothelial cells under chronic wound conditions. Experimental Cell Research, 2012, 318, 207-216.	2.6	39
71	Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease. Biochemical Society Transactions, 2011, 39, 1226-1232.	3.4	85
72	Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Research and Therapy, 2011, 13, R208.	3.5	56

#	Article	IF	CITATIONS
73	Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling. Immunology Letters, 2011, 138, 161-168.	2.5	15
74	Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells. Clinical Cancer Research, 2011, 17, 5626-5637.	7.0	32
75	Basic Science for Rheumatology. , 2011, , 1-38.		0
76	Changes in Apoptotic Gene Expression in Lymphocytes from Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Compared with Healthy Lymphocytes. Journal of Clinical Immunology, 2010, 30, 649-658.	3.8	17
77	Peroxiredoxin 2 in Human Inflammatory Joint Disease. Free Radical Biology and Medicine, 2010, 49, S151.	2.9	0
78	Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)–mediated apoptosis of T cells. Arthritis and Rheumatism, 2010, 62, 2919-2929.	6.7	50
79	Assessing association of common variation in the C1Q gene cluster with systemic lupus erythematosus. Clinical and Experimental Immunology, 2010, 161, 284-289.	2.6	19
80	Identification of a self-association domain in the Ewing's sarcoma protein: a novel function for arginine-glycine-glycine rich motifs?. Journal of Biochemistry, 2010, 147, 885-893.	1.7	17
81	Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle, 2010, 9, 3144-3149.	2.6	25
82	Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Molecular Cancer, 2010, 9, 301.	19.2	58
83	A Mechanism of Release of Calreticulin from Cells During Apoptosis. Journal of Molecular Biology, 2010, 401, 799-812.	4.2	87
84	Calreticulin: nonâ€endoplasmic reticulum functions in physiology and disease. FASEB Journal, 2010, 24, 665-683.	0.5	339
85	Hyperbaric oxygen treatment induces platelet aggregation and protein release, without altering expression of activation molecules. Clinical Biochemistry, 2009, 42, 467-476.	1.9	9
86	Identification of a tripartite import signal in the Ewing Sarcoma protein (EWS). Biochemical and Biophysical Research Communications, 2009, 390, 1197-1201.	2.1	13
87	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. Journal of Molecular Medicine, 2008, 86, 909-924.	3.9	37
88	Joining the dots: Production, processing and targeting of U snRNP to nuclear bodies. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 2137-2144.	4.1	23
89	Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists. Cancer Research, 2008, 68, 597-604.	0.9	47
90	Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein. Molecular Therapy, 2008, 16, 1919-1926.	8.2	29

#	Article	IF	CITATIONS
91	Determination of S-Nitrosothiols in Biological and Clinical Samples Using Electron Paramagnetic Resonance Spectrometry with Spin Trapping. Methods in Enzymology, 2008, 441, 151-160.	1.0	4
92	EpCAM-targeted induction of apoptosis. Frontiers in Bioscience - Landmark, 2008, Volume, 5042.	3.0	3
93	The innate immune component ficolin 3 (Hakata antigen) mediates the clearance of late apoptotic cells. Arthritis and Rheumatism, 2007, 56, 1598-1607.	6.7	119
94	Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends in Molecular Medicine, 2006, 12, 382-393.	6.7	123
95	CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood, 2006, 107, 2863-2870.	1.4	53
96	Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1543-1556.	6.7	119
97	Targeting the messengers of death: the advent of selective activation of apoptosis for cancer therapy. Discovery Medicine, 2006, 6, 113-7.	0.5	Ο
98	Target Cell–Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7. Cancer Research, 2005, 65, 3380-3388.	0.9	83
99	Variations in Helicobacter pylori Lipopolysaccharide To Evade the Innate Immune Component Surfactant Protein D. Infection and Immunity, 2005, 73, 7677-7686.	2.2	55
100	Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR. Journal of Biological Chemistry, 2005, 280, 10025-10033.	3.4	88
101	Immune Function of C1q and Its Modulators CD91 and CD93. Critical Reviews in Immunology, 2005, 25, 305-330.	0.5	35
102	Binding and Agglutination of Streptococcus pneumoniae by Human Surfactant Protein D (SP-D) Vary between Strains, but SP-D Fails To Enhance Killing by Neutrophils. Infection and Immunity, 2004, 72, 709-716.	2.2	34
103	Granule Localization of Glutaminase in Human Neutrophils and the Consequence of Glutamine Utilization for Neutrophil Activity. Journal of Biological Chemistry, 2004, 279, 13305-13310.	3.4	44
104	Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis, 2004, 25, 2115-2123.	2.8	74
105	Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. International Journal of Cancer, 2004, 109, 281-290.	5.1	85
106	Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells. Neoplasia, 2004, 6, 636-645.	5.3	49
107	Calreticulin's Role(s) in Autoimmune Disorders. Molecular Biology Intelligence Unit, 2003, , 180-192.	0.2	3
108	Introduction to Calreticulin. Molecular Biology Intelligence Unit, 2003, , 1-8.	0.2	4

#	Article	IF	CITATIONS
109	Expression of Surfactant Protein D in the Human Gastric Mucosa and during Helicobacter pylori Infection. Infection and Immunity, 2002, 70, 1481-1487.	2.2	57
110	The Anti-adhesive Activity of Thrombospondin Is Mediated by the N-terminal Domain of Cell Surface Calreticulin. Journal of Biological Chemistry, 2002, 277, 37219-37228.	3.4	103
111	Physical and Functional Interaction Between Cell-Surface Calreticulin and the Collagen Receptors Integrin α2β1 and Glycoprotein VI in Human Platelets. Thrombosis and Haemostasis, 2002, 88, 648-654.	3.4	37
112	Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets. Thrombosis and Haemostasis, 2002, 88, 648-54.	3.4	19
113	A calreticulin-like molecule from the human hookwormNecator americanusinteracts with C1q and the cytoplasmic signalling domains of some integrins. Parasite Immunology, 2001, 23, 141-152.	1.5	103
114	The ins and outs of calreticulin: from the ER lumen to the extracellular space. Trends in Cell Biology, 2001, 11, 122-129.	7.9	303
115	The conformation of calreticulin is influenced by the endoplasmic reticulum lumenal environment. Journal of Biological Chemistry, 2000, 275, 27177-85.	3.4	61
116	Thrombospondin Mediates Focal Adhesion Disassembly through Interactions with Cell Surface Calreticulin. Journal of Biological Chemistry, 2000, 275, 36358-36368.	3.4	177
117	Expression and Purification of Mammalian Calreticulin in Pichia pastoris. Protein Expression and Purification, 2000, 20, 207-215.	1.3	16
118	The Conformation of Calreticulin Is Influenced by the Endoplasmic Reticulum Luminal Environment. Journal of Biological Chemistry, 2000, 275, 27177-27185.	3.4	109
119	Lung surfactant proteins involved in innate immunity. Current Opinion in Immunology, 1999, 11, 28-33.	5.5	74
120	Pathophysiological Roles of Calreticulin in Autoimmune Disease. Scandinavian Journal of Immunology, 1999, 49, 466-473.	2.7	67
121	C1q—how many functions? How many receptors?. Trends in Cell Biology, 1998, 8, 428-431.	7.9	81
122	Evidence That C1q Binds Specifically to CH2-like Immunoglobulin γ Motifs Present in the Autoantigen Calreticulin and Interferes with Complement Activationâ€. Biochemistry, 1998, 37, 17865-17874.	2.5	64
123	C1q-mediated chemotaxis by human neutrophils: involvement of gClqR and G-protein signalling mechanisms. Biochemical Journal, 1998, 330, 247-254.	3.7	63
124	Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochemical Journal, 1997, 322, 543-550.	3.7	74
125	Modular organization of carbohydrate recognition domains in animal lectins. Matrix Biology, 1997, 15, 583-592.	3.6	43
126	A second serine protease associated with mannan-binding lectin that activates complement. Nature, 1997, 386, 506-510.	27.8	799

#	Article	IF	CITATIONS
127	Identification of Functional Domains on gClQ-R, a Cell Surface Protein That Binds to the Globular "Heads" of C1Q, Using Monoclonal Antibodies and Synthetic Peptides. Hybridoma, 1996, 15, 333-342.	0.6	61
128	Identification of a gC1q-binding protein (gC1q-R) on the surface of human neutrophils. Subcellular localization and binding properties in comparison with the cC1q-R Journal of Clinical Investigation, 1995, 95, 1569-1578.	8.2	66
129	Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses Journal of Clinical Investigation, 1994, 94, 311-319.	8.2	297
130	Heterogeneity in the circulating neutrophil pool: studies on subpopulations separated by continuous flow electrophoresis. Journal of Leukocyte Biology, 1992, 51, 617-625.	3.3	20
131	Prospects for graduates. Nature, 1992, 355, 292-292.	27.8	1
132	Hunterian Institute. Nature, 1992, 360, 203-203.	27.8	0
133	Priming action of inositol hexakisphosphate (InsP6) on the stimulated respiratory burst in human neutrophils. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1094, 309-316.	4.1	30
134	Dynamic changes in neutrophil cytoskeleton during priming and subsequent surface stimulated functions. Biochemical Society Transactions, 1991, 19, 1048-1055.	3.4	12
135	Population Heterogeneity in Blood Neutrophils Fractionated. ACS Symposium Series, 1991, , 190-205.	0.5	4
136	Rapid method for the isolation of neutrophils in high yield without the use of dextran or density gradient polymers. Journal of Immunological Methods, 1989, 121, 105-113.	1.4	106
137	Safety and efficacy of hyperbaric oxygen therapy in chronic wound management: current evidence. Chronic Wound Care Management and Research, 0, , 81.	0.4	15